← Markets
FDA moves BPC-157 to Category 1 by…?

FDA moves BPC-157 to Category 1 by…?

Resolves Dec 31, 2026·$123 24h vol·politics
$856 total volume·Open for 7 days

December 31, 2026

45%-3.5%
OutcomeYesNo
December 31, 2026
August 31, 2026

Order Book

December 31, 2026

PriceSharesTotal
96.0¢2.0k$1.9k
95.0¢10$10
94.0¢9$8
91.0¢1.1k$1.0k
90.0¢2.7k$2.4k
88.0¢16$14
87.0¢9$8
62.0¢12$8
60.0¢112$67
59.0¢9$6
70.0¢last trade
29.0¢ spread
30.0¢15$5
29.0¢37$11
27.0¢12$3
10.0¢10$1
9.0¢6$1
8.0¢180$14
6.0¢1.1k$63
5.0¢1.1k$57
4.0¢1.4k$56
3.0¢2.1k$62
$273 bids$5.5k asks

Resolution Criteria

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

December 31, 2026

45%